Cyclooxygenase (COX)-2, the inducible key enzyme for prostanoid biosynthesis, is overexpressed in most colorectal carcinomas and a subset of colorectal adenomas. Genetic, biochemical, and clinical evidence indicates an important role for COX-2 in colorectal tumorigenesis. Although COX-2 can be induced by aberrant growth factor signaling and oncogene activation during colorectal tumorigenesis, the role of microenvironmental factors such as hypoxia in COX-2 regulation remains to be elucidated. For the first time, we report that under hypoxic conditions COX-2 protein levels increase in colorectal adenoma and carcinoma cells. Rigorous analyses reveal that COX-2 up-regulation is transcriptional and is associated with hypoxia-inducible factor (HIF)-1A induction. Oligonucleotide pull-down and chromatin immunoprecipitation assays reveal that HIF-1A binds a hypoxia-responsive element on the COX-2 promoter. COX-2 up-regulation during hypoxia is accompanied by increased levels of prostaglandin E 2 (PGE 2 ), which promote tumor cell survival under hypoxic conditions. In addition, elevated levels of PGE 2 in hypoxic colorectal tumor cells enhance vascular endothelial growth factor expression and HIF-1 transcriptional activity by activating the mitogen-activated protein kinase pathway, showing a potential positive feedback loop that contributes to COX-2 up-regulation during hypoxia. This study identifies COX-2 as a direct target for HIF-1 in colorectal tumor cells. In addition, COX-2 up-regulation represents a pivotal cellular adaptive response to hypoxia with implication for colorectal tumor cell survival and angiogenesis. We propose that using modified COX-2-selective inhibitors, which are only activated under hypoxic conditions, could potentially be a novel more selective strategy for colorectal cancer prevention and treatment. (Cancer Res 2006; 66(13): 6683-91) 
Introduction
Colorectal cancer results from the accumulation of intrinsic genetic and epigenetic changes that alter signaling pathways, which regulate cell proliferation, differentiation, and cell death (1) as well as the selection process imposed by environmental and microenvironmental factors, which ultimately leads to clonal evolution and tumor progression (2) . Cyclooxygenase (COX)-2 is overexpressed in most colorectal carcinomas and a subset of adenomas (3, 4) , and accumulating evidence supports an important role for COX-2 in colorectal tumorigenesis (5) . COX-2-selective inhibitors have a potent antitumor effect in vitro (6, 7) and in vivo (8) , and genetic depletion of the COX-2 gene results in a marked decrease in adenoma burden in the Apc D716 mouse model of intestinal tumorigenesis (9) . Enhanced COX-2 expression in colon cancer cells results in increased levels of proangiogenic factors, such as vascular endothelial growth factor (VEGF), thus the promotion of angiogenesis (10) . COX-2, like its isoenzyme COX-1, catalyses the conversion of arachidonic acid to endoperoxide intermediates, which are ultimately converted to prostanoids. Recent evidence points to an important role for the COX-2 downstream metabolite prostaglandin E 2 (PGE 2 ) in colorectal tumorigenesis (11) . Increased levels of PGE 2 were reported in human colorectal cancers and adenomas in familial adenomatous polyposis (FAP) patients (12) . Additionally, PGE 2 can stimulate cell proliferation and motility (13) while inhibiting apoptosis in colorectal cancer cells (14) . More recently, PGE 2 was shown to enhance intestinal adenoma growth via activation of the Rasmitogen-activated protein kinase (MAPK) cascade in Apc min mice (15) . Given the critical role for COX-2 up-regulation in colorectal cancer and other cancers, it is important to achieve a greater understanding of the regulatory networks that control COX-2 expression.
Numerous factors, including growth factors, cytokines, oncogenes, and tumor promoters, stimulate COX-2 transcription via transcription factors, such as activator protein, NF-IL6, NF-nB, NFAT, and PEA3 (5) . In the context of colorectal tumorigenesis, although mutations resulting in aberrant Wnt and Ras signaling have been implicated in COX-2 up-regulation (16) , the role of microenvironmental factors, such as hypoxia in COX-2 regulation during colorectal tumorigenesis, has not been investigated.
Hypoxia, which refers to oxygen deficiency in tissues, is a universal hallmark of solid tumors and it represents a key regulatory factor in tumor growth and survival (17) . Although, the hypoxic microenvironment is thought to be associated with tumor progression (18) , persistent hypoxia can also result in cell death (19) . Therefore, hypoxia represents an important selection pressure that drives clonal progression of tumors (20) . Adaptation to hypoxia is critical for tumor cell survival and is mediated largely by activation of genes that facilitate short-term adaptation (e.g., increased vascular permeability) as well as long-term adaptive mechanisms (e.g., angiogenesis; refs. 17, 21, 22) .
The coordinated homeostatic response to hypoxia is largely transcriptional and is mediated primarily through the activation of the heterodimeric transcription factor hypoxia-inducible factor (HIF)-1 (23) . HIF-1 is composed of two subunits: the oxygensensitive HIF-1a and the constitutively expressed HIF-1h subunit (23) . In normoxia, HIF-1a is hydroxylated at key proline residues facilitating von Hippel-Lindau protein binding, which in turn allows ubiquitination and subsequent proteasome-targeted degradation (24) . Under hypoxic conditions, proline hydroxylation is inhibited, thereby stabilizing HIF-1a, which can then translocate into the nucleus and bind to constitutively expressed HIF-1h, forming the active HIF-1 complex (25) . The HIF-1 complex recruits the transactivator p300/CBP, resulting in enhanced transcriptional activity (26) . HIF-1 binds a conserved DNA consensus on promoters of its target genes known as the hypoxia-responsive element (HRE; ref. 23 ). The core sequence of the HRE is 5 ¶-CGTG-3 ¶, and the optimum mammalian HRE was defined to be 5 ¶-B(A/G)CGTGVBBB-3 ¶ (where B refers to all bases except A and V refers to all bases except T; ref. 27) .
HIF-1a is overexpressed in various types of cancer, including colorectal cancer (28) , and compelling evidence supports a role for HIF-1 in tumorigenesis (29, 30) . The HIF-1 transcriptional response largely allows cellular adaptation to the hypoxic microenvironment (31) . Therefore, identification and characterization of the mechanisms underlying the adaptive responses to hypoxia are vital for an increased understanding of the tumorigenic process and, most importantly, for the development of novel therapeutic approaches.
Because COX-2 expression increases during colorectal tumor progression (3, 4) and given the key role of COX-2 in colorectal tumorigenesis (9), we hypothesized that COX-2 may be a hypoxiaresponsive gene whose up-regulation may facilitate adaptation to cellular stress imposed by hypoxia. Indeed, we describe a novel mechanism for COX-2 up-regulation in colorectal tumor cells during hypoxia through HIF-1. During hypoxia, COX-2 upregulation results in higher levels of PGE 2 , which then promotes colorectal tumor cell survival. We also report that PGE 2 can enhance HIF-1 transcriptional activity and VEGF induction under hypoxic conditions. Collectively, our results identify COX-2 upregulation as a critical adaptive response to hypoxia with implications for colorectal tumor cell survival and angiogenesis.
Materials and Methods
Cell culture and treatments. The carcinoma cell lines HT29 and HCT116 were from the American Type Culture Collection (ATCC; Rockville, MD) and cultured in DMEM or McCoy's 5A media supplemented with 10% fetal bovine serum, respectively. The adenoma cell line AA/C1 was derived in this laboratory and maintained as described previously (2) . AA/C1 is derived from a single adenoma from a patient with FAP, and AA/C1/SB10C represents an in vitro-transformed variant of AA/C1 (2). For hypoxic exposure, cells were placed in a modulator-incubator in an atmosphere consisting of 94% N 2 , 5% CO 2 , and 1% O 2 . PGE 2 , the COX-2-selective inhibitor NS-398, and the hypoxia surrogate deferoxamine were from Sigma (Poole, United Kingdom). The MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor U0126 was from Cell Signalling Technology (Danvers, MA). The HIF-1a inhibitor YC-1 (32) , also an activator of soluble guanylyl cyclase, was from Cayman Europe (Tallinn, Estonia).
Determination of cell yield and cell death. After treatment, the cell yield was determined by counting the adherent cells. The level of cell death was assessed by measuring the proportion of floating apoptotic cells, which had detached from the tissue culture flask, and cell death was represented as a percentage of total cell number as described previously (33) . The induction of cell death was characterized as apoptotic both morphologically ( following acridine orange staining) and biochemically as shown by poly(ADP-ribose) polymerase cleavage as described in detail previously (33) .
Cell cycle analysis. Adherent HT29 cells were collected and fixed in 70% ethanol. Cells were resuspended in PBS containing 10 Ag/mL propidium iodide (Sigma) and 5 Ag/mL RNaseA (Sigma) and incubated at room temperature for 30 minutes before fluorescence-activated cell sorting analysis was done using a FACScan (BD Biosciences, Oxford, United Kingdom). Data analysis was done using Cell Quest software (BD Biosciences).
Transient transfection and reporter assays. The expression vector pcDNA3/HIF-1a/P402A+P564G (generous gift from Peter Ratcliffe, University of Oxford, Oxford, United Kingdom) encodes a mutant version of HIF-1a, which is resistant to degradation (34) . HT29 cells were transiently transfected with either HIF-1a expression plasmid or empty vector (pcDNA3) plasmid using Tfx (Promega, Southampton, United Kingdom) following the manufacturer's protocol.
The HRE reporter p11w was from the ATCC, and the COX-2 promoter reporter was a generous gift from Stephen Prescott (University of Utah, Salt Lake City, UT). COX-2 promoter deletions were carried out starting from the full-length COX-2 promoter using unique restriction sites and subcloned into a pGL3-basic vector. For luciferase reporter assays, HT29 cells were transfected with the firefly luciferase reporter construct and the control renilla luciferase reporter pRL-SV40 using Tfx reagent. After treatment, the luciferase activity was measured using the dual-luciferase reporter assay system (Promega) following the manufacturer's protocol.
Western blot analysis. Whole-cell extracts were prepared by lysing cells with Cell Signalling Technology lysis buffer supplemented with protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Protein concentration was quantified using Bio-Rad D C protein assay kit (BioRad, Hemel Hempstead, United Kingdom). Protein lysates were resolved on SDS-PAGE, and proteins were detected by Western blotting with mouse monoclonal antibodies against HIF-1a, HIF-1h (BD Biosciences), COX-2 (Cayman Europe), and a-tubulin (Sigma) and rabbit antibodies against ERK and pERK using enhanced chemiluminescence detection system (Kirkegaard & Perry Laboratories, Gaithersburg, MD).
RNA extraction and Northern analysis. Total RNA was isolated using the RNeasy kit (Qiagen, Crawley, United Kingdom). RNA (20 Ag) samples were resolved on a 1% formaldehyde agarose gel and analyzed by Northern blotting. COX-2 mRNAs were detected using a biotinylated human COX-2 probe. The COX-2 probe was prepared by amplifying a fragment from COX-2 cDNA using the biotinylated primers: forward primer (5 ¶-GTGCCTGAT-GATTGCCCGACTCC-3 ¶) and reverse primer (5 ¶-TGTTGTGTTCCCGCAGC-CAGATTG-3 ¶). Visualization was carried out using the nonradioactive North2South hybridization and detection kit (Pierce Biotechnology, Rockford) following the manufacturer's protocol. Oligonucleotide pull-down assay. Nuclear DNA-binding protein extracts (100 Ag) were incubated at 30jC for 10 minutes with either 0.5 nmol 5 ¶-biotinylated double-stranded wild-type (WT) oligonucleotide (5 ¶-ATTTTCTCATTTCCGTGGGTAAAAAACCCT-3 ¶) or mutant oligonucleotide (5 ¶-ATTTTCTCATTTCTACAGGTAAAAAACCCT-3 ¶) (Sigma-Genosys, Haverhill, United Kingdom) coupled previously to streptavidin agarose beads (Sigma). After incubation, the biotinylated oligonucleotide-coupled streptavidin beads were washed six times. Samples were denatured in SDS sample buffer and subjected to SDS-PAGE. HIF-1a was detected by Western blotting. For the competition assay, excess nonbiotinylated oligonucleotides were used.
Chromatin immunoprecipitation assay. The procedure was done using chromatin immunoprecipitation (ChIP) kit (Upstate, Lake Placid, NY). Briefly, HT29 cells growing in T25 flasks under normoxia or hypoxia were cross-linked using 1% formaldehyde at 37jC for 10 minutes. After washing with PBS, cells were resuspended in 300 AL lysis buffer [50 mmol/L TrisHCl (pH 8.1), 10 mmol/L EDTA, 1% SDS, protease inhibitor cocktail]. DNA was sheared to small fragments of 200 to 900 bp by sonication. The supernatant was recovered, diluted, and precleared using herring sperm DNA/protein G-Sepharose slurry (Sigma). The recovered supernatant was incubated with either anti-HIF-1a antibody or an isotype control IgG for 2 hours in the presence of herring sperm DNA and protein G-Sepharose beads. The beads were washed with low-salt, high-salt, and LiCl buffers. The immunoprecipitated DNA was retrieved from the beads with 1% SDS and 1.1 mol/L NaHCO 3 solution at 65jC for 6 hours. DNA was then purified using a PCR purification kit (Qiagen), and PCR was done on the extracted DNA using COX-2 promoter-specific primers forward (5 ¶-GAATTTACCTTTCCCGCCTCTC-3 ¶) and reverse (5 ¶-AAGCCCGGTGGG-GGCAGGGTTT-3 ¶).
VEGF quantification. VEGF level was determined in growth medium using a VEGF ELISA (R&D Systems, Arbington, United Kingdom) following the manufacturer's instructions. The growth medium was removed and cleared by centrifugation, and adherent cells were counted. The level of VEGF was determined in samples at two different dilutions (1:1 and 1:10) in triplicate and standardized to cell number.
Determination of PGE 2 levels. PGE 2 levels were measured using a competitive enzyme immunoassay for PGE 2 (Cayman Europe) following the manufacturer's protocol.
Statistical analysis. Statistical tests were carried out using t test done on Microsoft Excel. Statistical significance was determined and expressed as P V 0.01.
Results
COX-2 protein expression is up-regulated in colorectal tumor cells in response to hypoxia. To achieve a further understanding of the regulatory networks controlling COX-2 expression, we sought to investigate the role of an important microenvironmental factor, hypoxia, in COX-2 regulation. For this, colorectal carcinoma (HT29 and HCT116), colorectal adenoma (AA/C1), and in vitro-transformed adenoma (AA/C1/SB10C) cells were subjected to growth under hypoxic conditions (1% O 2 ), and protein extracts were prepared over time (Fig. 1A) . Immunoblot analysis confirmed that cells were exposed to hypoxia, as HIF-1a was rapidly induced in both colorectal adenoma and carcinoma cells (Fig. 1A) . Interestingly, COX-2 protein levels increased in a time-dependent manner on exposure to hypoxia in all the cell lines used (Fig. 1A) irrespective of the basal levels of COX-2 expressed by these cells. It is important to note that, in response to hypoxia, HIF-1a induction preceded COX-2 up-regulation (Fig. 1A ) . Interestingly, COX-1 protein levels did not change in response to hypoxia in any of the cell lines used (data not shown).
COX-2 is transcriptionally up-regulated during hypoxia. Having shown COX-2 up-regulation by hypoxia in colorectal tumor cells, we aimed to gain some insights into the mechanism underlying this up-regulation. Initially, we used a luciferase reporter assay using a COX-2 promoter to assess the COX-2 Figure 1 . COX-2 up-regulation in colorectal tumor cells during hypoxia. A, Western blot analyses for HIF-1a and COX-2 protein levels during hypoxia. Colorectal tumor cell lines (carcinoma cells, HT29 and HCT116; adenoma cells, AA/C1; and in vitro-transformed adenoma, AA/C1/SB10C), which express different basal levels of COX-2 (6, 50), were exposed to hypoxia (1% O 2 ), and HIF-1a and COX-2 protein levels were analyzed by Western blotting over time as indicated. a-Tubulin was used as a protein loading control. B, HT29 cells were transiently transfected with the COX-2 promoter luciferase reporter and pRL-SV40 plasmids and grown in either normoxia (N ) or hypoxia (H ) for 16 hours. The luciferase activity was determined. Columns, mean of three independent experiments; bars, SD. C, Northern blot analysis for COX-2 mRNA levels in HT29 cells exposed to hypoxia for the indicated time using a biotinylated COX-2 probe. The 18S rRNA was used as a control for equal loading. D, examination of COX-2 mRNA decay in HT29 cells after growth in hypoxia/normoxia. HT29 cells were exposed to hypoxia/normoxia for 16 hours and transferred to normoxia after treatment with 10 Amol/L actinomycin-D. Cells were harvested every hour over a 3-hour period, and COX-2 mRNA levels were analyzed by Northern blotting. -1a) expression vector, and the levels of HIF-1a and COX-2 were analyzed by Western blotting. A, right, effect of HIF-1a inhibition on COX-2 up-regulation during hypoxia in HT29 cells. HT29 cells were exposed to hypoxia in the presence of increasing concentrations of the guanylyl cyclase inhibitor YC-1 for 16 hours and then followed by Western blotting for HIF-1a and COX-2. B, nucleotide sequence of the COX-2 promoter. Bold uppercase letters, core sequences of the four HREs, CGTG; bold lowercase letters, transcription start point; underlined, restriction sites used in the subcloning of shorter fragments of the COX-2 promoter. Diagrammatic representation of the progressively shorter fragments of the COX-2 promoter [full length (P1), deleted HRE1 (P2), deleted HRE1 and HRE2 (P3 ), and deleted HRE3 (P4 )] and their relative location. Relative luciferase reporter activity of the different promoter constructs after transfection in HT29 cells and exposure to hypoxia. Columns, mean of three independent experiments done in triplicates; bars, SD. C, top, oligonucleotides used in the pull-down assay. The WT oligonucleotide corresponds to fragment À519 to À490 from the COX-2 promoter [highlighted in (B )] and contains a HRE core sequence (underlined , position À506); this sequence was mutated in the mutant (Mut ) oligonucleotide (underlined ). C, bottom , oligonucleotide pull-down assay. HT29 cells were grown in normoxia or hypoxia for 16 hours, and nuclear protein extracts were prepared. The pull-down assay was done as described in Materials and Methods, samples were denatured and resolved on SDS-PAGE, and then blots were probed with HIF-1a monoclonal antibody. D, ChIP assay. HT29 cells were grown in normoxia/hypoxia for 16 hours, cells were then fixed and lysed, and DNA was sheared by sonication to 200-to 900-bp fragments (DNA shearing efficacy was assessed by gel electrophoresis). Immunoprecipitation was carried out using an HIF-1a monoclonal antibody or an irrelevant mouse IgG. The protein DNA complexes were denatured, and DNA was recovered and purified using a PCR purification kit. A PCR using COX-2 promoter primer was done on the input (genomic DNA) from normoxia-and hypoxia-treated HT29 cells as well as the immunoprecipitated DNA (using HIF-1a and mouse IgG). PCR products were analyzed by gel electrophoresis, and the size of the COX-2 promoter fragment was determined using the DNA marker (M ).
promoter activity during hypoxia. Exposure of HT29 to hypoxia for 16 hours resulted in an f3-fold increase in COX-2 promoter reporter activity compared with normoxia (Fig. 1B) , suggesting that hypoxia may enhance transcription from the COX-2 promoter. This observation was supported by Northern blot analysis, revealing that COX-2 mRNA levels increased in HT29 cells growing under hypoxic conditions in a time-dependent manner (Fig. 1C) . To further confirm that the increase in COX-2 mRNA levels is a result of transcriptional activation rather than mRNA stabilization, the rate of COX-2 mRNA decay following the inhibition of transcription was examined. HT29 cells growing in hypoxia for 16 hours were transferred to normoxia after treatment with 10 Amol/L actinomycin-D. Cells were harvested every hour over a 3-hour period, and COX-2 mRNA levels were analyzed by Northern blotting. The results revealed similar kinetics of COX-2 mRNA decay in cells growing in normoxia (Fig. 1D) , suggesting that hypoxia does not confer stabilization of COX-2 mRNA. Taken together, these data suggested that COX-2 is a hypoxia-responsive gene, whose expression can be transcriptionally enhanced in colorectal tumor cells on exposure to hypoxia.
COX-2 up-regulation is associated with HIF-1A induction. Because COX-2 was transcriptionally up-regulated in hypoxic HT29 cells and given the critical role that HIF-1 plays in the cellular transcriptional response to hypoxia, we investigated whether HIF-1 is involved in hypoxia-mediated COX-2 up-regulation. To examine the association between HIF-1a induction and COX-2 upregulation, HT29 cells were treated with increasing concentrations of the hypoxia surrogate deferoxamine (a specific HIF-1a inducer) for 16 hours. Western blot analysis revealed the deferoxamine treatment induced HIF-1a and also increased COX-2 protein levels in HT29 cell in a dose-dependent manner ( Fig. 2A, left) . Additionally, transient ectopic expression of HIF-1a in HT29 cells, achieved by transfection with a mutant HIF-1a that is resistant to degradation (34), resulted in f2.5-fold increase in COX-2 protein levels in normoxia compared with HT29 cells transfected with the vector-only control plasmid ( Fig. 2A, middle) . This increase in COX-2 protein levels was consistent in several experiments, ranging from 2-to 3-fold. Furthermore, inhibiting HIF-1a induction during hypoxia using 200 Amol/L YC-1 (32) abolished hypoxia-mediated COX-2 up-regulation ( Fig. 2A, right) . Altogether, these observations suggest that HIF-1 is involved in hypoxia-induced COX-2 up-regulation.
HIF-1 directly binds to the COX-2 promoter. Having established an association between HIF-1a induction and COX-2 up-regulation, a direct involvement for HIF-1 in COX-2 transcription was investigated. HIF-1 has been shown to bind HRE on promoters of target genes and activate their transcription (23) . Screening of the COX-2 promoter region for HIF-1-binding sites revealed the presence of four putative HRE consensuses Figure 3 . The effect of COX-2 up-regulation on colorectal cancer cell growth and survival during hypoxia. A, COX-2 up-regulation during hypoxia results in increased PGE 2 levels. HT29 cells were exposed to normoxia or hypoxia in the presence or absence of 10 Amol/L COX-2-selective inhibitor NS-398 for 24 hours, and then PGE 2 levels were determined in the growth medium using a commercial ELISA and standardized to cell number. Columns, mean of three experiments done in triplicate; bars, SD. B, effect of hypoxia on cell growth and survival during hypoxia. HT29 cells were exposed to normoxia or hypoxia for 24 hours, and the number of adherent and floating apoptotic cells were determined as described in Materials and Methods. Columns, mean of three independent experiments done in triplicate; bars, SD. (*, P V 0.01). B, bottom, Based on DNA content, cell cycle analyses were also done on HT29 cells growing in normoxia and hypoxia. The data are examples of one experiment done six times independently. C, PGE 2 promotes cancer cell growth and survival under hypoxic conditions. HT29 cells were treated in hypoxia with NS-398 (10 Amol/L), PGE 2 (1 Amol/L), or a combination of both for 24 hours to examine the effect of PGE 2 on cell growth and survival under hypoxic conditions. The number of attached and floating apoptotic cells were determined as described in Materials and Methods. Columns, mean of three different experiments done in triplicate; bars, SD.
(HRE1, HRE2, HRE3, and HRE4) in the sense orientation (Fig. 2B) . From these four HRE sites, only the HRE3 (5 ¶-GACGTGACTT-3 ¶) located at position 506 upstream the transcription initiation point (À506) fulfilled the criteria for mammalian HRE. Indeed, COX-2 promoter deletion analysis suggested the importance of HRE3 in the responsiveness of COX-2 promoter to hypoxia, as deletion of HRE3 abolished hypoxia-mediated activation of the COX-2 promoter reporter (Fig. 2B) . To test the physical interaction of HIF-1 with the HRE3 of the human COX-2 promoter, we used biotinylated double-stranded oligonucleotides (Fig. 2C) coupled to streptavidin agarose beads to pull-down proteins interacting with the HRE3 in HT29 cells growing in normoxia or hypoxia. The bound protein complexes were then analyzed by Western blotting. As shown in Fig. 2C , HIF-1a bound to the WT HRE3 oligonucleotide but not to a similar oligonucleotide with the HRE3 mutated. The binding capacity of HIF-1a to the WT oligonucleotide decreased progressively with the addition of increasing amounts of the nonbiotinylated WT oligonucleotide in a competition assay (Fig. 2C) . These results indicate that HIF-1a directly binds the HRE3 derived from the COX-2 promoter. We next did ChIP to determine whether HIF-1 binds the COX-2 promoter in HT29 cells. As shown in Fig. 2D , the anti-HIF-1a antibody, but not the control IgG antibody, precipitated the COX-2 promoter fragment spanning HRE3 in hypoxic HT29 cells. These data show that HIF-1 binds the COX-2 promoter at HRE3 site located at À506.
COX-2 up-regulation in hypoxia results in increased PGE 2 levels. Previous reports have shown a critical role for the COX-2 metabolite PGE 2 in colorectal tumorigenesis (15) . Having shown COX-2 up-regulation in hypoxia, we examined whether PGE 2 levels also increase in hypoxia. HT29 cells were subjected to growth under hypoxic conditions in the presence or absence of the COX-2-selective inhibitor NS-398 for 16 hours, and the levels of PGE 2 in the growth medium were determined. There was a 4-fold increase in PGE2 levels in hypoxia compared with normoxia (Fig. 3A) . Furthermore, the increase in PGE 2 during hypoxia was inhibited by treatment with 10 Amol/L COX-2-selective inhibitor NS-398 (this dose was reported previously to selectively inhibit COX-2 activity with no effect on cell growth; ref. 35) . Therefore, we conclude that, in response to hypoxia, there is a COX-2-dependent increase in PGE 2 levels.
PGE 2 contributes to tumor cell growth and survival under hypoxic conditions. PGE 2 has been shown previously to promote colorectal tumor cell growth and survival in normoxia (13, 14) . This is believed to be one of the mechanisms underlying the oncogenic role of COX-2 in colorectal tumorigenesis. Here, we hypothesized that the increased levels of PGE 2 during hypoxia may also promote cell growth and survival under hypoxic conditions. Initially, exposure of HT29 cells to hypoxia for 24 hours resulted in a reduction in cell yield (Fig. 3B, top, left) , increased levels of cell death (Fig. 3B, top, right) , and a decreased rate of cell proliferation with more cells accumulating in G 1 phase of the cell cycle (Fig. 3B, bottom) . To assess the direct consequence of COX-2 on cell survival under hypoxia, COX-2 was selectively inhibited with 10 Amol/L COX-2-selective inhibitor NS-398, and cell yield was determined. In normoxia, NS-398 (10 Amol/L) treatment had no significant effect on cell yield (data not shown; reported in ref. 35) , and as predicted, PGE 2 treatment on its own significantly enhanced cell growth (data not shown; reported in ref. 36 ). In hypoxia, NS-398 (10 Amol/L) treatment potentiated the inhibitory effect of hypoxia on cell yield (Fig. 3C,  top) with a significant increase in cell death (Fig. 3C, bottom) . /L) , or a combination of both for 16 hours. Western blot analyses were used to assess HIF-1a/HIF-1h protein levels. An HRE luciferase reporter assay was used as described in Materials and Methods to assess HIF-1 transcriptional activity after treatment with PGE 2 . B, increased PGE 2 levels during hypoxia result in enhanced VEGF production. HT29 cells were treated as described previously, and VEGF level was determined in the growth medium using a commercial ELISA. Columns, mean of three independent experiments standardized to cell counts; bars, SD.
The inhibitory effect of NS-398 on cell survival under hypoxia was overcome by the addition of exogenous PGE 2 (Fig. 3C) . Treatment with PGE 2 on its own promoted cancer cell growth and survival in hypoxia (Fig. 3C) . Taken together, these results indicated that PGE 2 as a result of COX-2 activity plays an important role in promoting colorectal cancer cell growth and survival during hypoxia.
PGE 2 enhances HIF-1 transcriptional activation during hypoxia. To examine a possible cross-talk between COX-2/PGE 2 and HIF-1 pathways, we decided to investigate whether PGE 2 affected HIF-1 expression or activity. PGE 2 , at relatively high concentrations, has been reported previously to increase the expression of HIF-1a in HCT116 cells (37) . In normoxia, PGE 2 alone at a relatively low dose (1 Amol/L) that we have shown previously to stimulate growth and survival of colorectal cancer cells (36) failed to induce HIF-1a (Fig. 4A ) and had no effect on HIF-1h levels. Similarly, under hypoxic conditions, exogenous PGE 2 (1 Amol/L) and NS-398 (10 Amol/L) treatment had no effect on HIF-1a/HIF-1h expression levels (Fig. 4A) . Interestingly, however, hypoxia-induced HIF-1 transcriptional activity was partly inhibited by NS-398 treatment, suggesting that PGE 2 may enhance HIF-1 transcriptional activity in hypoxia (Fig. 4A) . Indeed, subsequent addition of PGE 2 overcame the inhibitory effect of NS-398 on HIF-1 transactional activity. These observations suggest that PGE 2 enhances HIF-1 transcriptional activity in hypoxia.
VEGF, the critical proangiogenesis factor, is an important target of HIF-1. As PGE 2 enhances HIF-1 transcriptional activity in hypoxia, we examined the role of PGE 2 in VEGF regulation. PGE 2 treatment resulted in the induction of VEGF in HT29 cells growing under normoxia (Fig. 4B) . Exposing HT29 cells to hypoxia resulted in a further increase in VEGF production, which was partly inhibited by NS-398. The inhibitory effect of NS-398 on VEGF expression under hypoxia was recovered by PGE 2 treatment (Fig. 4B ). These observations correlate with HIF-1 transcriptional activity shown in Fig. 4A and indicated that PGE 2 potentiates hypoxia-induced VEGF by enhancing HIF-1 transcriptional activity in the colon cancer cell line HT29.
PGE 2 enhances HIF-1 transcriptional activity in hypoxia through the MAPK pathway. PGE 2 has been shown to promote cell proliferation through the activation of MAPK pathway (15); we therefore examined whether increased levels of PGE 2 during hypoxia activate the MAPK pathway. Consistent with previous reports, in normoxia, PGE 2 activated the MAPK pathways by inducing ERK phosphorylation in HT29 cells (Fig. 5A) . In hypoxia, ERK was also activated, and its activation was partly inhibited with NS-398 treatment (Fig. 5A) . However, the inhibitory effect of NS-398 on ERK activation in hypoxia was overcome by PGE 2 treatment (Fig. 5A) . These results indicate that increased levels of PGE 2 during hypoxia activate the MAPK pathway.
Because the MAPK pathway has been reported to enhance HIF-1 transcriptional activity (38) , it was hypothesized that increased levels of PGE 2 by hypoxia may increase HIF-1 activity through activating the MAPK pathway. To test this hypothesis, HIF-1 activity was assessed in hypoxic HT29 cells treated with the MEK inhibitor U0126. Inhibition of MEK resulted in reduced transcriptional activity of HIF-1 similar to that observed with NS-398 treatment (Fig. 5B) . However, whereas the addition of PGE 2 overcame the effect of NS-398 on HIF-1 transcriptional activity, PGE 2 did not reverse the effect of the MEK inhibitor. This suggests that PGE 2 enhances HIF-1 transcriptional activity through ERK activation.
Discussion
Adaptation to hypoxia is critical for tumor cell growth and survival and is achieved largely by transcriptional activation of genes that facilitate short-and long-term adaptive responses (17, 31) . In the current study, we report for the first time that hypoxia induces COX-2 in colorectal tumor cells and show that this up-regulation is mediated directly by HIF-1. In addition, COX-2 upregulation by hypoxia represents a critical adaptive mechanism that promotes colorectal tumor cell survival and angiogenesis under hypoxic conditions. COX-2 overexpression has been described in tumors originating from different tissues (39) , including colorectal tumors (3, 4) , and compelling evidence supports an important role for COX-2 in tumorigenesis (8, 40, 41) . Therefore, identifying the regulatory mechanisms that underlie COX-2 up-regulation is crucial for further understanding of the tumorigenic process and the development of novel approaches for cancer prevention and therapy. For colorectal tumors, deregulation of the Wnt and Ras signaling pathways have been reported to contribute to COX-2 up-regulation (16) . Our findings identify hypoxia as a novel tumor microenvironmental factor that contributes to COX-2 up-regulation in colorectal tumor cells. It is of interest to note that, in response to hypoxia, COX-2 expression Figure 5 . PGE 2 activates the MAPK pathway during hypoxia and enhances HIF-1 transcriptional activity through ERK activation. A, Western blot analysis was carried out to examine ERK activation in HT29 cells grown in normoxia/ hypoxia in the presence or absence of NS-398, PGE 2 , or both. B, PGE 2 enhances HIF-1 transcriptional activity through ERK activation. HT29 cells were exposed to growth under hypoxic conditions and treated as indicated, and, subsequently, ERK activation and HIF-1 transcriptional activity were examined.
is enhanced in both colorectal adenoma and carcinoma cells, suggesting that hypoxia may contribute to COX-2 overexpression at early stages of colorectal tumorigenesis. Additionally, hypoxia upregulates COX-2 expression in colorectal tumor cells with different basal levels of COX-2, suggesting that hypoxia may act synergistically with other pathways implicated in COX-2 up-regulation.
COX-2 up-regulation by hypoxia has been described previously in human umbilical vascular endothelial (42) and corneal epithelial cells (43) to be mediated by NF-nB and peroxisome proliferatoractivated receptors, respectively. In addition, while this article was in preparation, Csiki et al. reported that COX-2 is up-regulated in hypoxic lung cancer cells in an HIF-1-dependent manner (44) . Although the study of Csiki et al. was the first report to describe COX-2 as a HIF-1 target gene, we provide the first evidence to show that HIF-1 directly binds a specific HRE located at À506 on the COX-2 promoter and highlight the biological significance of COX-2 upregulation during hypoxia. The oncogenic role of COX-2 in colorectal and other tumors is largely attributed to its role in prostaglandin biosynthesis (11) . For colorectal tumorigenesis, PGE 2 has been particularly and extensively studied (11) . Here, we report that COX-2 up-regulation in hypoxia results in enhanced PGE 2 production. Given the pivotal role of PGE 2 in promoting colorectal tumor cell growth and survival, the results obtained in this work are particularly relevant to explain, at least in part, how colorectal tumor cells maintain their growth and survival under hypoxic conditions. Until now, great emphasis has been placed on the role of COX-2/PGE 2 in tumor cell growth and survival under normoxic conditions, mediated by activating phosphatidylinositol 3-kinase/MAPK pathways (13) as well as up-regulating the prosurvival protein Bcl-2 (14) . Our data provide further insight into the critical role of COX-2/PGE 2 in promoting cell survival most importantly under hypoxic microenvironmental stress, which is typically known to inhibit cell growth (45) and, if persistent, cell death can ensue (19, 29) . The increase in COX-2 and PGE 2 levels in hypoxic colorectal tumor cells represents a novel short-term adaptive response that allows cell survival during hypoxia, which could have important implications for colorectal tumorigenesis. Although the mechanisms by which PGE 2 promotes cell survival in hypoxia are not completely elucidated here, our data supported by previous reports (13, 15) suggest that it is likely to be occurring through the activation of MAPK.
In addition to mediating short-term survival and metabolic responses in tumors, hypoxia also induces long-term responses (i.e., angiogenesis; ref. 22) , mediated chiefly by the secretion of VEGF (46) . Recent reports showed that PGE 2 can activate the ''angiogenic switch'' in COX-2-induced breast cancer progression (47) . For colorectal tumors, in particular, COX-2 plays a critical role in VEGF induction and stimulation of angiogenesis (10) . The data reported here not only emphasize the important role of PGE 2 in increasing VEGF levels in colorectal cancer cells in normoxia but also reveal that increased PGE 2 levels during hypoxia enhance hypoxia-mediated VEGF up-regulation. This potentiation is achieved by the effect of PGE 2 in enhancing the transcriptional activity of HIF-1 through the activation of MAPK pathway, consistent with previous reports that described the involvement of MAPK pathways in the modulation of HIF-1 transcriptional activity (38) . These findings highlight a cross-talk between HIF-1 and COX-2 pathway (Fig. 6 ). The ability of PGE 2 to potentiate HIF-1 transcriptional activity is particularly interesting because HIF-1 is involved in the regulation of several other pathways implicated in tumorigenesis (48) . Therefore, PGE 2 up-regulation in colorectal tumor cells during hypoxia may modulate the expression of several other HIF-1-target genes, which could have implications for tumor cell survival, angiogenesis, invasion and metastasis, and subsequently tumor progression (Fig. 6) .
The link between hypoxia and COX-2 established in this study suggests possible overlapping functions that collectively drive the progression of colorectal and potentially other solid tumors where hypoxia is commonly observed. Recently, PGE 2 has been shown to amplify the expression of COX-2 during colorectal tumorigenesis through a positive feedback loop involving the constitutive activation of Ras-MAPK (15); this observation can be extended to our study. Increased levels of PGE 2 during hypoxia, resulting from COX-2 up-regulation, potentiate HIF-1 transcriptional activity, which results in further up-regulation of COX-2 because we showed that COX-2 is a HIF-1 target gene. This positive feedback loop may be important in maintaining COX-2 overexpression in hypoxic colorectal tumor cells (Fig. 6) .
In summary, our findings provide further evidence that hypoxia promotes tumor progression by modulating gene expression. In colorectal tumor cells, COX-2 is transcriptionally induced by hypoxia via HIF-1, and its up-regulation contributes to maintaining tumor survival and potentially promoting angiogenesis. Thus, COX-2 overexpression can be regarded as a critical adaptive response to hypoxia, which mediates both short-(survival) and long-term adaptation (angiogenesis). Because tumor hypoxia could be a target for selective cancer therapy (49), our findings suggest that pharmacologic targeting of COX-2 using modified COX-2-selective inhibitors that can only be activated under hypoxic conditions could increase the selectivity of the current COX-2-selective inhibitors.
